Tags : Xenon


Neurocrine Signs a License Agreement with Xenon to Develop Therapies

Shots: Neurocrine to receive exclusive license to Xenon’s XEN901 including two preclinical candidates including selective Nav1.6 inhibitors and dual Nav1.2/1.6 inhibitors involving activities to discover, develop and identify additional novel Nav1.6 and Nav1.2/1.6 inhibitors  Neurocrine Biosciences will fund all clinical developments costs associated with products including funding of 3 years research collaboration with a minimum […]Read More